Literature DB >> 26847773

Hepatic Transporter Expression in Metabolic Syndrome: Phenotype, Serum Metabolic Hormones, and Transcription Factor Expression.

Ajay C Donepudi1, Qiuqiong Cheng1, Zhenqiang James Lu1, Nathan J Cherrington1, Angela L Slitt2.   

Abstract

Metabolic syndrome is a multifactorial disease associated with obesity, insulin resistance, diabetes, and the alteration of multiple metabolic hormones. Obesity rates have been rising worldwide, which increases our need to understand how this population will respond to drugs and exposure to other chemicals. The purpose of this study was to determine in lean and obese mice the ontogeny of clinical biomarkers such as serum hormone and blood glucose levels as well as the physiologic markers that correlate with nuclear receptor- and transporter-related pathways. Livers from male and female wild-type (WT) (C57BL/6) and ob/ob mice littermates were collected before, during, and after the onset of obesity. Serum hormone and mRNA levels were analyzed. Physiologic changes and gene expression during maturation and progression to obesity were performed and correlation analysis was performed using canonical correlations. Significant ontogenic changes in both WT and ob/ob mice were observed and these ontogenic changes differ in ob/ob mice with the development of obesity. In males and females, the ontogenic pattern of the expression of genes such as Abcc3, 4, Abcg2, Cyp2b10, and 4a14 started to differ from week 3, and became significant at weeks 4 and 8 in ob/ob mice compared with WT mice. In obese males, serum resistin, glucagon, and glucose levels correlated with the expression of most hepatic ATP-binding cassette (Abc) transporters, whereas in obese females, serum glucagon-like peptide 1 levels were correlated with most hepatic uptake transporters and P450 enzymes. Overall, the correlation between physiologic changes and gene expression indicate that metabolism-related hormones may play a role in regulating the genes involved in drug metabolism and transport.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26847773      PMCID: PMC4810770          DOI: 10.1124/dmd.115.066779

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  46 in total

1.  Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulin-resistant and type 2 diabetic state.

Authors:  P Moreno; A Acitores; I Gutiérrez-Rojas; B Nuche-Berenguer; M El Assar; L Rodriguez-Mañas; R Gomis; I Valverde; M Visa; W J Malaisse; A Novials; N González; M L Villanueva-Peñacarrillo
Journal:  Peptides       Date:  2011-09-16       Impact factor: 3.750

Review 2.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

3.  The traditional ayurvedic medicine, Eugenia jambolana (Jamun fruit), decreases liver inflammation, injury and fibrosis during cholestasis.

Authors:  Ajay C Donepudi; Lauren M Aleksunes; Maureen V Driscoll; Navindra P Seeram; Angela L Slitt
Journal:  Liver Int       Date:  2011-12-30       Impact factor: 5.828

4.  UDP-glucuronosyltransferase expression in mouse liver is increased in obesity- and fasting-induced steatosis.

Authors:  Jialin Xu; Supriya R Kulkarni; Liya Li; Angela L Slitt
Journal:  Drug Metab Dispos       Date:  2011-10-26       Impact factor: 3.922

Review 5.  Drug-drug interactions with glucagon-like peptide-1 receptor agonists.

Authors:  Kathryn M Hurren; Nicole R Pinelli
Journal:  Ann Pharmacother       Date:  2012-04-17       Impact factor: 3.154

6.  Alteration of hepatic but not renal transporter expression in diet-induced obese mice.

Authors:  Vijay R More; Angela L Slitt
Journal:  Drug Metab Dispos       Date:  2011-03-23       Impact factor: 3.922

7.  Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease.

Authors:  Nicole J Barshop; Edmund V Capparelli; Claude B Sirlin; Jeffrey B Schwimmer; Joel E Lavine
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-02       Impact factor: 2.839

8.  Fasting induces nuclear factor E2-related factor 2 and ATP-binding Cassette transporters via protein kinase A and Sirtuin-1 in mouse and human.

Authors:  Supriya R Kulkarni; Ajay C Donepudi; Jialin Xu; Wei Wei; Qiuqiong C Cheng; Maureen V Driscoll; Delinda A Johnson; Jeffrey A Johnson; Xiaoling Li; Angela L Slitt
Journal:  Antioxid Redox Signal       Date:  2013-07-31       Impact factor: 8.401

9.  Gene expression of ATP-binding cassette transporters during liver regeneration after 90% hepatectomy in rats.

Authors:  Norihisa Kimura; Kenichi Hakamada; Shojiro-Kazunori Ikenaga; Yutaka Umehara; Yoshikazu Toyoki; Mutsuo Sasaki
Journal:  Int J Mol Med       Date:  2012-04-20       Impact factor: 4.101

10.  Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.

Authors:  Rhiannon N Hardwick; Craig D Fisher; Stephanie M Street; Mark J Canet; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2011-11-23       Impact factor: 3.922

View more
  5 in total

1.  Chimeric mouse model for MRI contrast agent evaluation.

Authors:  Faryal F Mir; Ryan P Tomaszewski; Dorela D Shuboni-Mulligan; Christiane L Mallett; Jeremy M L Hix; Nicholas D Ether; Erik M Shapiro
Journal:  Magn Reson Med       Date:  2019-03-15       Impact factor: 4.668

2.  Dynamic Contrast-Enhanced MRI of OATP Dysfunction in Diabetes.

Authors:  Dorela D Shuboni-Mulligan; Maciej Parys; Barbara Blanco-Fernandez; Christiane L Mallett; Regina Schnegelberger; Marilia Takada; Shatadru Chakravarty; Bruno Hagenbuch; Erik M Shapiro
Journal:  Diabetes       Date:  2018-11-28       Impact factor: 9.461

3.  Lack of Multidrug Resistance-associated Protein 4 Prolongs Partial Hepatectomy-induced Hepatic Steatosis.

Authors:  Ajay C Donepudi; Gregory J Smith; Oladimeji Aladelokun; Yoojin Lee; Steven J Toro; Marisa Pfohl; Angela L Slitt; Li Wang; Ji-Young Lee; John D Schuetz; José E Manautou
Journal:  Toxicol Sci       Date:  2020-06-01       Impact factor: 4.849

4.  Multidrug resistance-associated protein 4 (Mrp4) is a novel genetic factor in the pathogenesis of obesity and diabetes.

Authors:  Ajay C Donepudi; Yoojin Lee; Ji-Young Lee; John D Schuetz; José E Manautou
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.191

5.  Lack of multidrug resistance-associated protein 4 (Mrp4) alters the kinetics of acetaminophen toxicity.

Authors:  Ajay C Donepudi; Michael J Goedken; John D Schuetz; José E Manautou
Journal:  Toxicol Rep       Date:  2019-08-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.